DS
CRL icon

David Shaw’s Charles River Laboratories CRL Stock Holding History

David Shaw’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,500
Closed -$5.46M – 5592
2021
Q4 		$5.46M Buy
14,500
+8,000
+123% +$3.11M ﹤0.01% 2274
2021
Q3 		$2.68M Buy
+6,500
New +$2.7M ﹤0.01% 2735

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

David Shaw's CRL Position: Q2 2026 in Review

David Shaw reduced its Charles River Laboratories (CRL) stake by 84% in Q2 2026, selling an estimated $28.8M and leaving 31,587 shares worth $7.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

David Shaw first reported a position in CRL in Q2 2013 and has held it in 47 quarters since. The position peaked at $150M in Q3 2025. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • David Shaw held 31,587 shares of Charles River Laboratories worth $7.16M as of Q2 2026.
  • David Shaw sold 161,896 Charles River Laboratories shares in Q2 2026, an estimated $28.8M.
  • Charles River Laboratories made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2121 holding.
  • David Shaw first reported a position in Charles River Laboratories in Q2 2013 and has held it in 47 quarters since.
  • David Shaw's Charles River Laboratories position peaked at $150M in Q3 2025.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.